Centrica and Convatec share prices slump 25%+, but could they offer recovery potential?

Do shares in Centrica plc (LON: CNA) and Convatec Group plc (LON: CTEC) offer wide margins of safety?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The share price of global medical products and technologies company Convatec (LSE: CTEC) declined by as much as 30% on Monday following a profit warning. Of course, it is not the first stock to experience significant falls in its share price due to disappointing financial performance. FTSE 100-listed Centrica’s(LSE: CNA) share price has declined by 60% in the last five years.

Looking ahead, further volatility could be on the cards for both stocks. At the same time though, they may now offer wider margins of safety and could therefore provide more compelling investment potential for the long term.

Uncertain outlook

Convatec’s profit warning was due to a change in inventory policy by the biggest customer in its Infusion Devices franchise. This is expected to have a material negative impact on revenue in the fourth quarter of the year of $18m-$23m. The company also experienced challenging market dynamics in specific markets in its Advanced Wound Care segment which contributed to a difficult period for the business. As such, it now expects full-year organic revenue growth of between 0% and 1%. This is down from previous guidance of between 2.5% and 3%.

Alongside a profit warning, the company also announced that its CEO, Paul Maroviec, has decided to retire. He has stepped down as CEO with immediate effect and will be replaced on an interim basis by Rick Anderson, who is currently a non-executive director of the company.

Convatec is clearly in an uncertain period at the present time. Volatility could continue and investor sentiment may remain weak in the near term. However, with what seems to be a sound overall business, its prospects for a long-term recovery seem to be bright.

Recovery prospects

As mentioned, the Centrica share price has endured a challenging period in recent years. The company has experienced a mix of internal and external challenges that have combined to produce a disappointing performance for its investors. For example, it has suffered from a weak outlook for the oil and gas industry in recent years, while its decision to pivot towards domestic energy supply has caused investors to become concerned about regulatory and political risk to a greater extent.

Looking ahead, the company’s shares could become more popular if the world economy experiences a difficult period. They may provide a degree of defensive appeal for investors who are looking for companies which have lower correlation to the performance of the wider economy. Its dividend yield currently stands at 8%, and while it is covered just 1.1 times by profit, the company’s declining bottom line of recent years is due to come to an end in the current year.

Clearly, Centrica’s share price decline could continue in the near term. However, with what seems to be a sound strategy to improve its efficiency, the company could prove to be a sound turnaround opportunity over the coming years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Centrica. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing For Beginners

How to try and build a £250k Stocks and Shares ISA from scratch, starting in 2024

With a regular savings plan and a smart investment strategy, it’s possible to build wealth within a Stocks and Shares…

Read more »

Investing Articles

I’m considering 3 top UK dividend stocks for my portfolio this July

Mark David Hartley is looking at adding a few dividend stocks to his portfolio this month. Will these three shares…

Read more »

Investing Articles

3 FTSE 100 shares I’d buy to create lasting passive income

Dividend stocks are a great way to build an additional income. Our writer details three FTSE 100 picks she’d love…

Read more »

Investing Articles

After falling 9% in 6 weeks, is this FTSE 100 stock now in bargain territory?

The BAE Systems share price hit a 52-week high on 3 June. Six weeks later, it’s down nearly 10%. Is…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

I love the look of Entain shares, potentially 47% undervalued

Many FTSE 100 companies have been on a tear in 2024, but with Entain shares down nearly 50%, I think…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Could Aviva shares reach £5.84 in the next 12 months?

Some analysts think Aviva shares could soar nearly 19% in the next year. This Fool takes a closer look to…

Read more »

Investing Articles

I’m looking at a once-in-a-decade chance to buy dirt-cheap FTSE dividend shares

Harvey Jones says FTSE 100 dividend shares have been showing signs of life lately but they're still cheap and there's…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

If I’d put £10k in BAE Systems shares 10 years ago, here’s what I’d have now

BAE Systems shares have been on fire over the last decade. But just how much would a £10k investment back…

Read more »